U.S. Markets closed

AcelRx Pharmaceuticals, Inc. (ACRX)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
2.40-0.10 (-4.00%)
At close: 4:00PM EDT
People also watch
ALIMAVEOECYTAEGRINFI
  • PERCEPTIVE ADVISORS LLC sold their 875k shares on Monday @ $2.40. Bad idea for them, every swing up .10 is $87,500 missed for the investors. Right now up .13 or missed $113,750. They should have waited for $7.60 average price - Missed out another $4,500,000 that looks very likely for October. They must have needed the money now, to leave that much money on the table.
  • Don't forget Webcast
    AcelRx Pharmaceuticals, Inc. at the BIO 2017 International Convention (Live)
    06/21/17 at 11:45 a.m. PT
    Looks like they will be using old slides
    GLTA
  • Guess I missed my chance to pick up my last 20% block starting to run away on us here. Figure we would be around 4.50 around ADCOM recommendation.
    GLTA
  • ACRX Sale of 875000 shares at $2.40 per share by Beneficial Owner Perceptive Advisors Llc on 06/19
  • Monster MicroCaps SPECIAL ALERT to ACRX shareholders – NWBO $.19 and climbing, just announced $11 million financing with convertible debt payable in 3 years at $0.25, $.50 and $1.00. NWBO expected to release final Phase III Trial results any day from now until mid-July. If results are comparable to preliminary data, shares likely to explode to yield enormous percentage gains. Announcement could be huge because DCVax-L and DCVax Direct are also proven effective against 13 common cancers and has only mild fever as potential side effect. This breakthrough immunotherapy might replace the $100 Billion chemotherapy market.
    https://finance.yahoo.com/news/nwbio-closes-3-convertible-debt-154100683.html

    NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
    This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondhold
    finance.yahoo.com
  • Does FDA have to wait until Oct 12 2017 to grant approval? Could approval happen anytime review has been completed now that ADCOM is not required part of the process?
    GLTA
  • heavy volume
  • ADCOM may not be requirement. It was not listed on FDA register anyway. In hospital use under medically supervised setting. We don't know decision yet, PDUFA is intact. Outpatient opioids are the problem. Why not recall morphine? It's ridiculous. You could drink morphine, lol. This is for in hospital just the same as giving any CII in hospital via a doctor's order. This is not for prescription from retail CVS or Rite Aid.
  • Looks like we are in trouble based on the PPS. I don't recall bad news. What is driving this?
  • Was today capitulation?
  • Medication is comparatively safe and certainly safer then what is currently being used, it is already used and growing in Europe, good data, military has believed in it, invested in it, needs and wants it, trump president (whatever your political affiliation)...'nuff said

    October will be a good month. Once it's approved it is that much easier to approve zalviso which is a second potential gigantic revenue stream (ask a nurse what a pain mso4 pump is....beep beep beep. $&@? It!!!!)

    It's the summer there are no catalysts it needs approval, that's your catalyst. Patience
  • hard to believe based on PPS... but no ADCOM might actually be a positive. No real questions. Sufentanil very well understood for many decades. It is a good option for DOD and ER. Little risk of abuse since not available as prescription. Company has been working on filing for many years.
  • AcelRx looks like the smart guys in the room by supervised control use of its product. The FDA requested removal of Opana ER for risks related to abuse is what happens when you rush to market. Baby steps in the process with an eye on the finish line is what they are preforming. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm

    FDA requests removal of Opana ER for risks related to abuse
    Today, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based o
    www.fda.gov
  • Short interest up 850,000 shares in the latest two weeks measured
    Up over 4,5 million shares short
    Hasn't been so high for almost a year
    Long but concerned
    GLTA
  • How about this for an idea? Let's all personally show up to the annual shareholders meeting June 15th and ask all these valid questions of this board presents.
  • @Siamese Kitty
    "So they will review safety and efficacy and provide a REMS to go over"
    Without ADCOM is this something PDUFA review can/will advise the company on REMS?
    If no CRL and no ADCOM why would the FDA still wait until Oct 12? If there are NO issues why not just approve it?
    GLTA
  • I think the fact that ACRX's safety data is good, it's inaccessibility in pharmacies and necessity by the military in the field in the end will prevail. These medications will never completely be eliminated, they are here to stay and are necessary and completely appropriate in many situations of uncontrolled pain.
    Pharma has to work out systems and government has to demand systems to prevent abuse.
  • Questions I would ask if I were able to attend the annual meeting.
    1) Why did Tim quit?
    2) Mr Adams in 2014 you spoke about significantly increasing shareholder value, when may that happen?
    3) Mr Vinny what is the plan? Please show us shareholders a little respect.
    4) Why did Tim really quit? personal reasons? health issues? disagreed with the direction of the company? caught doing something illegal/unethical? why did Tim quit?
  • The volume is so low that it looks like people who must sell are selling their shares. I'll be buying at every chance I get on this great opportunity. Their product line provides a solid value and will prove the company’ goals are viable and forward thinking.
  • Haven't seen anyone here post about FDA cancelling the AdCom for Dsuvia. It's not posted on Yahoo Finance either. ACRX – FDA has notified the Company that it no longer plans to hold an advisory committee meeting in connection with its review of the Company’s New Drug Application for DSUVIA.

    Jun 7, 2017 | 7:04am | By StockNews.com Staff